PMID- 35344301
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220406
IS  - 2045-7022 (Print)
IS  - 2045-7022 (Electronic)
IS  - 2045-7022 (Linking)
VI  - 12
IP  - 3
DP  - 2022 Mar
TI  - AllergoOncology: Role of immune cells and immune proteins.
PG  - e12133
LID - 10.1002/clt2.12133 [doi]
LID - e12133
AB  - BACKGROUND: Immune cells and immune proteins play a pivotal role in host 
      responses to pathogens, allergens and cancer. Understanding the crosstalk between 
      allergic response and cancer, immune surveillance, immunomodulation, role of 
      immunoglobulin E (IgE)-mediated functions and help to develop novel therapeutic 
      strategies. Allergy and oncology show two opposite scenarios: whereas immune 
      tolerance is desired in allergy, it is detrimental in cancer. AIM: The current 
      review provides an update on the role of immune cells and immune proteins in 
      allergy and cancer fields. METHODS: Authors investigated the role of relevant 
      immunological markers and the correlation with cancer progression or cancer 
      suppression. RESULTS: Activated immune cells such as macrophages 'M1', dendritic 
      cells (DCs), innate lymphoid cells (ILC2), NK cells, Th1, follicular T helper 
      cells (TFH), TCD8+, B lymphocytes and eosinophils have inhibitory effects on 
      tumourigenesis, while tolerogenic cells such as macrophages 'M2,' tolerogenic 
      DCs, ILC3, T and B regulatory lymphocytes appear to favour carcinogenesis. 
      Mastocytes and alarmins can have both effects. RIgE antibodies and CCCL5 
      chemokine have an anticancer role, whereas IgG4, free light chains, Il-10, TGF-beta, 
      lipocalin-2, CCL1 chemokine promote cancer progression. Fundamental is also the 
      contribution of epigenetic changes regulated by the microRNA in cancer 
      progression. CONCLUSION: This knowledge represents the key to developing new 
      anticancer therapies.
CI  - (c) 2022 The Authors. Clinical and Translational Allergy published by John Wiley & 
      Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
FAU - Di Gioacchino, Mario
AU  - Di Gioacchino M
AD  - Center for Advanced Science and Technology, G. d'Annunzio University, Chieti, 
      Italy.
AD  - IDA - Institute of Clinical Immunotherapy and Advanced Biological Treatments, 
      Pescara, Italy.
FAU - Della Valle, Loredana
AU  - Della Valle L
AD  - Center for Advanced Science and Technology, G. d'Annunzio University, Chieti, 
      Italy.
AD  - IDA - Institute of Clinical Immunotherapy and Advanced Biological Treatments, 
      Pescara, Italy.
FAU - Allegra, Alessandro
AU  - Allegra A
AD  - Division of Hematology, Department of Human Pathology in Adulthood and Childhood 
      'Gaetano Barresi', University of Messina, Messina, Italy.
FAU - Pioggia, Giovanni
AU  - Pioggia G
AUID- ORCID: 0000-0002-8089-7449
AD  - Institute for Biomedical Research and Innovation (IRIB), National Research 
      Council of Italy (CNR), Messina, Italy.
FAU - Gangemi, Sebastiano
AU  - Gangemi S
AD  - Department of Clinical and Experimental Medicine, School of Allergy and Clinical 
      Immunology, and Operative Unit of Allergy and Clinical Immunology, University of 
      Messina, Messina, Italy.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Clin Transl Allergy
JT  - Clinical and translational allergy
JID - 101576043
PMC - PMC8967267
OTO - NOTNLM
OT  - IgE
OT  - allergy
OT  - immune surveillance
OT  - immunomodulation
OT  - malignancy susceptibility
COIS- The authors declare no conflict of interest.
EDAT- 2022/03/29 06:00
MHDA- 2022/03/29 06:01
PMCR- 2022/03/28
CRDT- 2022/03/28 12:18
PHST- 2021/12/21 00:00 [revised]
PHST- 2021/08/28 00:00 [received]
PHST- 2022/02/18 00:00 [accepted]
PHST- 2022/03/28 12:18 [entrez]
PHST- 2022/03/29 06:00 [pubmed]
PHST- 2022/03/29 06:01 [medline]
PHST- 2022/03/28 00:00 [pmc-release]
AID - CLT212133 [pii]
AID - 10.1002/clt2.12133 [doi]
PST - ppublish
SO  - Clin Transl Allergy. 2022 Mar;12(3):e12133. doi: 10.1002/clt2.12133.